NCT05740163 Oral Immunotherapy for Egg Allergy in Children Aged 6 to 16
| NCT ID | NCT05740163 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tampere University Hospital |
| Condition | Egg Allergy |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2019-12-30 |
| Primary Completion | 2024-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2019-12-30 with a primary completion date of 2024-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of the study is to determine the efficacy of a 12-month egg oral immunotherapy (OIT) protocol with a cooked whole egg product including yolk and egg white. Study hypothesis: With this method the risk for severe allergic reaction to egg protein is reduced and the diet can partly or completely be normalized.
Eligibility Criteria
Inclusion Criteria: * Age 6 to 16 years * Elevated spesific serum IgE to egg (\> 5 kU/l) and/or positive skin prick to egg allergen * Positive oral food challenge for egg or anaphylaxis reaction to egg within the 6 months * Diet free from egg in any form Exclusion Criteria: * Age less than 6 years or more than 16 years * Poor asthma control or uncontrolled asthma * Severe/significant cardiovascular disease * Autoimmune disease * Malignancy * Medication: beta bloker, angiotensin-converting-enzyme inhibitors (ACE inhibitors), Monoamine oxidase inhibitors (MAOIs) * Poor compliance * Fear of immunotherapy * Desensitization to alfa-gal-protein (mammalian meat allergy)
Contact & Investigator
Rüdiger Schultz, MD., PhD
PRINCIPAL INVESTIGATOR
Tampere University Hospital
Frequently Asked Questions
Who can join the NCT05740163 clinical trial?
This trial is open to participants of all sexes, aged 6 Years or older, up to 16 Years, studying Egg Allergy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05740163 currently recruiting?
Yes, NCT05740163 is actively recruiting participants. Contact the research team at rudiger.schultz58@gmail.com for enrollment information.
Where is the NCT05740163 trial being conducted?
This trial is being conducted at Oulu, Finland, Tampere, Finland.
Who is sponsoring the NCT05740163 clinical trial?
NCT05740163 is sponsored by Tampere University Hospital. The principal investigator is Rüdiger Schultz, MD., PhD at Tampere University Hospital. The trial plans to enroll 60 participants.